|
1
|
Russo IH and Russo J: Role of hormones in
mammary cancer initiation and progression. J Mammary Gland Biol
Neoplasia. 3:49–61. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Russo J and Russo IH: The role of estrogen
in the initiation of breast cancer. J Steroid Biochem Mol Biol.
102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Orlando L, Schiavone P, Fedele P, et al:
Molecularly targeted endocrine therapies for breast cancer. Cancer
Treat Rev. 36(Suppl 3): S67–S71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Landeghem AA, Poortman J, Nabuurs M and
Thijssen JH: Endogenous concentration and subcellular distribution
of estrogens in normal and malignant human breast tissue. Cancer
Res. 45:2900–2906. 1985.PubMed/NCBI
|
|
5
|
Bulun SE, Lin Z, Imir G, et al: Regulation
of aromatase expression in estrogen-responsive breast and uterine
disease: from bench to treatment. Pharmacol Rev. 57:359–383. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bulun SE, Price TM, Aitken J, Mahendroo MS
and Simpson ER: A link between breast cancer and local estrogen
biosynthesis suggested by quantification of breast adipose tissue
aromatase cytochrome P450 transcripts using competitive polymerase
chain reaction after reverse transcription. J Clin Endocrin Metab.
77:1622–1628. 1993. View Article : Google Scholar
|
|
7
|
Yue W, Wang JP, Hamilton CJ, Demers LM and
Santen RJ: In situ aromatization enhances breast tumor estradiol
levels and cellular proliferation. Cancer Res. 58:927–932.
1998.PubMed/NCBI
|
|
8
|
Santen RJ and Harvey HA: Use of aromatase
inhibitors in breast carcinoma. Endocr Relat Cancer. 6:75–92. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brodie AM and Njar VC: Aromatase
inhibitors and their application in breast cancer treatment.
Steroids. 65:171–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hill SM and Blask DE: Effects of the
pineal hormone melatonin on the proliferation and morphological
characteristics of human breast cancer cells (MCF-7) in culture.
Cancer Res. 48:6121–6126. 1988.PubMed/NCBI
|
|
11
|
Cos S and Sánchez-Barceló EJ: Melatonin
and mammary pathological growth. Front Neuroendocrinol. 21:133–170.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blask DE, Sauer LA and Dauchy RT:
Melatonin as a chronobiotic/anticancer agent: cellular, biochemical
and molecular mechanisms of action and their implications for
circadian-based cancer therapy. Curr Topics Med Chem. 2:113–132.
2002. View Article : Google Scholar
|
|
13
|
Mediavilla MD, Sánchez-Barceló EJ, Tan DX,
Manchester L and Reiter RJ: Basic mechanisms involved in the
anti-cancer effects of melatonin. Curr Med Chem. 17:4462–4481.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sánchez-Barceló EJ, Cos S, Fernández R and
Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr
Relat Cancer. 10:153–159. 2003.
|
|
15
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ:
Estrogen-signaling pathway: a link between breast cancer and
melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin
as a selective estrogen enzyme modulator. Curr Cancer Drug Targets.
8:691–702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
González A, Cos S, Martínez-Campa C,
Alonso-González C, Sánchez-Mateos S, Mediavilla MD and
Sánchez-Barceló EJ: Selective estrogen enzyme modulator actions of
melatonin in human breast cancer cells. J Pineal Res. 45:86–92.
2008.PubMed/NCBI
|
|
18
|
Zhou D, Wang J, Chen E, Murai J, Siiteri
PK and Chen S: Aromatase gene is amplified in MCF-7 human breast
cancer cells. J Steroid Biochem Mol Biol. 46:147–153. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ram PT, Kiefer T, Silverman M, Song Y,
Brown GM and Hill SM: Estrogen receptor transactivation in MCF-7
breast cancer cells by melatonin and growth factors. Mol Cell
Endocrinol. 141:53–64. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ram PT, Dai J, Yuan L, Dong C, Kiefer TL,
Lai L and Hill SM: Involvement of the mt1 melatonin receptor in
human breast cancer. Cancer Lett. 179:141–150. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cos S, Martínez-Campa C, Mediavilla MD and
Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7
human breast cancer cells. J Pineal Res. 38:136–142. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cos S, González A, Güezmes A, Mediavilla
MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ:
Melatonin inhibits the growth of DMBA-induced mammary tumors by
decreasing the local biosynthesis of estrogens through the
modulation of aromatase activity. Int J Cancer. 118:274–278. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng L, Zhou J, Sasano H, Suzuki T,
Zeitoun KM and Bulun SE: Tumor necrosis factor α and interleukin 11
secreted by malignant breast epithelial cells inhibit adipocyte
differentiation by selectively down-regulating CCAAT/enhancer
binding protein α and peroxisome proliferator-activated receptor γ
mechanism of desmoplastic reaction. Cancer Res. 61:2250–2255.
2001.
|
|
24
|
Bulun SE, Chen D, Lu M, et al: Aromatase
excess in cancers of breast, endometrium and ovary. J Steroid
Biochem Mol Biol. 106:81–96. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes
in the desmoplastic reaction in breast cancer by regulating
cytokine production. J Pineal Res. 52:282–290. 2012.PubMed/NCBI
|
|
26
|
González A, Alvarez-García V,
Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes
differentiation of 3T3-L1 fibroblasts. J Pineal Res. 52:12–20.
2012.PubMed/NCBI
|
|
27
|
Harada N, Sasano H, Murakami H, Ohkuma T,
Nagura H and Takagi Y: Localized expression of aromatase in human
vascular tissues. Circ Res. 84:1285–1291. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mukherjee TK, Dinh H, Chaudhuri G and
Nathan L: Testosterone attenuates expression of vascular cell
adhesion molecule-1 by conversion to estradiol by aromatase in
endothelial cells: implications in atherosclerosis. Proc Natl Acad
Sci USA. 6:4055–4060. 2002. View Article : Google Scholar
|
|
29
|
Sebastian S and Bulun SE: A highly complex
organization of the regulatory region of the human CYP19
(aromatase) gene revealed by the human genome project. J Clin
Endocrinol Metab. 10:4600–4602. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bulun SE, Lin Z, Zhao H, Lu M, Amin S,
Reierstad S and Chen D: Regulation of aromatase expression in
breast cancer tissue. Ann NY Acad Sci. 1155:121–131. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen D, Reierstad S, Lu M, Lin Z, Ishikawa
H and Bulun SE: Regulation of breast cancer-associated aromatase
promoters. Cancer Lett. 273:15–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sebastian S, Takayama K, Shozu M and Bulun
SE: Cloning and characterization of a novel endothelial promoter of
the human CYP19 (aromatase P450) gene that is up-regulated in
breast cancer tissue. Mol Endocrinol. 10:2243–2254. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martínez-Campa C, González A, Mediavilla
MD, Alonso-González C, Álvarez-García V, Sánchez-Barceló EJ and Cos
S: Melatonin inhibits aromatase promoter expression by regulating
cyclooxygenases expression and activity in breast cancer cells. Br
J Cancer. 101:1613–1619. 2009.PubMed/NCBI
|
|
34
|
González A, Martínez-Campa C, Mediavilla
MD, et al: Effects of MT1 melatonin receptor
overexpression on the aromatase-supressive effect of melatonin in
MCF-7 human breast cancer cells. Oncol Rep. 4:947–953. 2007.
|
|
35
|
Cui P, Luo Z, Zhang H, et al: Effect and
mechanism of melatonin's action on the proliferation of human
umbilical vein endothelial cells. J Pineal Res. 4:358–362.
2006.
|
|
36
|
Cui P, Yu M, Luo Z, Dai M, Han J, Xiu R
and Yang Z: Intracellular signaling pathways involved in cell
growth inhibition of human vein endothelial cells by melatonin. J
Pineal Res. 44:107–114. 2008.PubMed/NCBI
|
|
37
|
Ackerman GE, Smith ME, Mendelson CR,
MacDonald PC and Simpson ER: Aromatization of androstenedione by
human adipose tissue stromal cells in monolayer culture. J Clin
Endocrinol Metab. 53:412–417. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pasqualini JR: The selective estrogen
enzyme modulators in breast cancer: a review. Biochim Biophys Acta.
1654:123–143. 2004.PubMed/NCBI
|
|
39
|
Pasqualini JR and Chetrite GS: Recent
insight on the control of enzymes involved in estrogen formation
and transformation in human breast cancer. J Steroid Biochem Mol
Biol. 93:221–236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cos S and Sánchez-Barceló EJ: Melatonin,
experimental basis for a possible application in breast cancer
prevention and treatment. Histol Histopathol. 15:637–647.
2000.PubMed/NCBI
|
|
41
|
Molis TM, Spriggs LI and Hill SM:
Modulation of estrogen receptor mRNA expression by melatonin in
MCF-7 human breast cancer cells. Mol Endocrinol. 8:1681–1690.
1994.PubMed/NCBI
|
|
42
|
Hill SM, Spriggs LL, Simon MA, Muraoka H
and Blask DE: The growth inhibitory action of melatonin on human
breast cancer cells is linked to the estrogen response system.
Cancer Lett. 64:249–256. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Garvin S, Nilsson UW and Dabrosin C:
Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1 and
VEGFR-2 in breast cancer and endothelial cells. Br J Cancer.
9:1005–1010. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
González A, Martínez-Campa C, Mediavilla
MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Inhibitory
effects of pharmacological doses of melatonin on aromatase activity
and expression in rat glioma cells. Br J Cancer. 97:755–760.
2007.PubMed/NCBI
|
|
45
|
Knower KC, To SQ, Takagi K, Miki Y, Sasano
H, Simpson ER and Clyne CD: Melatonin suppresses aromatase
expression and activity in breast cancer associated fibroblasts.
Breast Cancer Res Treat. 132:765–771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Turner HE, Harris AL, Melmed S and Wass
JA: Angiogenesis in endocrine tumors. Endocr Rev. 24:600–632. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
García-Santos G, Antolín I, Herrera F,
Martín V, Rodriguez-Blanco J, del Pilar Carrera M and Rodriguez C:
Melatonin induces apoptosis in human neuroblastoma cancer cells. J
Pineal Res. 41:130–135. 2006.
|
|
48
|
Sainz RM, Mayo JC, Tan DX, Leon J,
Manchester L and Reiter RJ: Melatonin reduces prostate cancer cell
growth leading to neuroendocrine differentiation via a receptor and
PKA independent mechanism. Prostate. 63:29–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Longatti P, Perin A, Rizzo V, Comai S,
Giusti P and Costa CV: Ventricular cerebrospinal fluid melatonin
concentrations investigated with an endoscopic technique. J Pineal
Res. 42:113–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Maestroni GJ and Conti A: Melatonin in
human breast cancer tissue: association with nuclear grade and
estrogen receptor status. Lab Invest. 75:557–561. 1996.PubMed/NCBI
|
